Enveric Biosciences, Inc. (ENVB) stock
ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.44−0.07 (-4.95%)
Close on Nov 16, 2026Market cap $6.45MP/E –Yield –
Enveric Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Enveric Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.56M. For fiscal 2025 it was -$8.14M. The highest annual figure on record is -$21.63K in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.14M | – |
| FY2024 | Dec 31, 2024 | -$7.73M | – |
| FY2023 | Dec 31, 2023 | -$14.09M | – |
| FY2022 | Dec 31, 2022 | -$17.15M | – |
| FY2021 | Dec 31, 2021 | -$11.46M | – |
| FY2020 | Dec 31, 2020 | -$3.89M | – |
| FY2019 | Dec 31, 2019 | -$647.86K | – |
| FY2018 | Dec 31, 2018 | -$2.57M | – |
| FY2017 | Dec 31, 2017 | -$2.74M | – |
| FY2016 | Dec 31, 2016 | -$2.70M | – |
| FY2015 | Dec 31, 2015 | -$3.90M | – |
| FY2014 | Dec 31, 2014 | -$43.16K | – |
| FY2013 | Dec 31, 2013 | -$21.63K | – |
| FY2012 | Dec 31, 2012 | -$24.85K | – |
| FY2011 | Dec 31, 2011 | -$30.35K | – |
| FY2010 | Dec 31, 2010 | -$40.67K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.44M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.78M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.07M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.89M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.39M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$927.07K | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.60M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.74M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.46M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.55M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.16M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.25M | -372.3% |
| Q3 FY2020 | Sep 30, 2020 | -$393.74K | – |
| Q2 FY2020 | Jun 30, 2020 | -$351.13K | – |
| Q1 FY2020 | Mar 31, 2020 | -$893.92K | – |
| Q4 FY2019 | Dec 31, 2019 | $826.30K | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | -$490.02K | -371.9% |
| Q1 FY2019 | Mar 31, 2019 | -$984.13K | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.00M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.28M | – |
| Q2 FY2018 | Jun 30, 2018 | $180.21K | – |
| Q1 FY2018 | Mar 31, 2018 | -$459.56K | – |
| Q4 FY2017 | Dec 31, 2017 | -$941.22K | -420.6% |
| Q3 FY2017 | Sep 30, 2017 | -$98.58K | – |
| Q2 FY2017 | Jun 30, 2017 | -$863.06K | – |
| Q1 FY2017 | Mar 31, 2017 | -$837.93K | – |
| Q4 FY2016 | Dec 31, 2016 | $293.58K | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.83M | – |
See a number that looks wrong?